Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.62 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
| ▸ | IL1B | P01584 | 1/20 | 0.62 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.45 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288757 | 0.93 | CRBN (0.54) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20288531 | 0.93 | CRBN (0.54) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20329516 | 0.85 | CRBN (0.57) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20263323 | 0.85 | CRBN (0.57) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20263450 | 0.84 | CRBN (0.56) | CRBNIKZF3DDB1BRD4TNF | |
| Hydrochloric Acid SCHEMBL38657800 | 0.83 | CRBN (0.55) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL24132668 | 0.82 | CRBN (0.55) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20263314 | 0.81 | CRBN (0.54) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20263438 | 0.81 | CRBN (0.54) | CRBNIKZF3DDB1BRD4TNF | |
| SCHEMBL20263297 | 0.81 | CRBN (0.54) | CRBNIKZF3DDB1BRD4TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3559005-A1 | THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Biotheryx Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180298027-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2018-10-18 | — | — | US | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2018118947-A1 | THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| EP-2093228-B1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2012-02-22 | — | — | EP | disclosed |
| US-20100152240-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-06-17 | — | — | US | disclosed |
| EP-2093228-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885DDB1 2309/4885 |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, CKS2 | CRBN 1205/4885IKZF3 2/4885DDB1 2584/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885DDB1 2309/4885 |
| US-20100152240-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, CYC1 | CRBN 2750/4885IKZF3 2702/4885DDB1 1368/4885 |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885DDB1 2309/4885 |
| US-20180298027-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885DDB1 2309/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885DDB1 2309/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885DDB1 2309/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | CRBN 1160/4885IKZF3 2/4885DDB1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.